SCHEMBL179720

SCHEMBL179720

Oc1ccc2c(c1)Oc1cc(O)ccc1C2(O)c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 7/20 0.49
HPGD P15428 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
MAPT P10636 1/20 0.49
CYP2C19 P33261 1/20 0.49
HTT P42858 1/20 0.49
RECQL P46063 1/20 0.49
BLM P54132 1/20 0.49
SMAD3 P84022 1/20 0.49
PRMT1 Q99873 1/20 0.49
ACE2 Q9BYF1 1/20 0.49
BRCA1 P38398 2/20 0.47
HSD17B10 Q99714 2/20 0.47
ALDH1A1 P00352 1/20 0.47
CYP2C9 P11712 1/20 0.47
ALOX15 P16050 1/20 0.47
ALOX12 P18054 1/20 0.47
TRPA1 O75762 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14740590 0.84 FTO (0.50) FTOHPGDMEN1KMT2ATDP1
SCHEMBL29452872 0.84 FTO (0.50) FTOHPGDMEN1KMT2ATDP1
SCHEMBL418120 0.81 MAPT (0.42) FTOHPGDMEN1KMT2ATDP1
SCHEMBL9810556 0.81 FTO (0.48) FTOHPGDMEN1KMT2ATDP1
SCHEMBL29722 0.79 CHRM3 (0.46) MEN1KMT2ATDP1CYP2C19CYP2C9
SCHEMBL31085589 0.77 FTO (0.44) FTOHPGDMEN1KMT2ATDP1
SCHEMBL9594691 0.77 FTO (0.44) FTOHPGDMEN1KMT2ATDP1
SCHEMBL14022367 0.77 HPGD (0.39) FTOHPGDMEN1KMT2ATDP1
SCHEMBL16200992 0.76 FTO (0.43) FTOHPGDMEN1KMT2ATDP1
SCHEMBL12939881 0.76 FTO (0.50) FTOHPGDMEN1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 555 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8076072-B2 Nucleic acid labeling compounds AFFYMETRIX, INC. (US) 2011-12-13 US claimed
US-8026057-B2 Nucleic acid labeling compounds AFFYMETRIX, INC. (US) 2011-09-27 US claimed
US-7468243-B2 Nucleotide sequence labelling compoumd four use as tool in genetic engineering AFFYMETRIX, INC. (US) 2008-12-23 US claimed
US-7291463-B2 Incubating/condensating pseudoisocytidine molecule with (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to provide a pseudouridine molecule; oncology diagnosis AFFYMETRIX, INC. (US) 2007-11-06 US claimed
US-7282327-B2 Nucleic acid labeling compounds AFFYMETRIX, INC. (US) 2007-10-16 US claimed
US-11993772-B2 Linking sequence reads using paired code tags ILLUMINA, INC. (US) 2024-05-28 US disclosed
US-20230406874-A1 FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE ILLUMINA, INC. 2023-12-21 US disclosed
CN-116888143-A Method for determining collagen content by using collagen hybrid peptide 3螺旋有限公司 2023-10-13 CN disclosed
US-11760772-B2 Functionalization and purification of molecules by reversible group exchange ILLUMINA, INC. (US) 2023-09-19 US disclosed
US-20210277043-A1 FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE ILLUMINA, INC. (US) 2021-09-09 US disclosed
US-11021504-B2 Functionalization and purification of molecules by reversible group exchange ILLUMINA, INC. (US) 2021-06-01 US disclosed
US-11008567-B2 Oligonucleotide replacement for di-tagged and directional libraries ILLUMINA, INC. (US) 2021-05-18 US disclosed
WO-1979000882-A1 MACROMOLECULAR ENVIRONMENT CONTROL IN SPECIFIC RECEPTOR ASSAYS SYVA CO (US) 1979-11-01 WO disclosed
US-4161515-A DETECTING ANTILIGAND WITH LIGAND-ANALOG FLUORESCER SYVA COMPANY (US) 1979-07-17 US disclosed
US-4160016-A Receptor fluorescent immunoassay SYVA COMPANY (US) 1979-07-03 US disclosed
US-4130462-A Receptor steric hindrance immunoassay for receptor determination SYVA COMPANY (US) 1978-12-19 US disclosed
US-3998943-A Double receptor fluorescent immunoassay SYVA COMPANY (US) 1976-12-21 US disclosed
US-3996345-A Fluorescence quenching with immunological pairs in immunoassays SYVA COMPANY (US) 1976-12-07 US disclosed
US-3939350-A Fluorescent immunoassay employing total reflection for activation BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 1976-02-17 US disclosed
US-3935074-A Antibody steric hindrance immunoassay with two antibodies SYVA COMPANY (US) 1976-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230406874-A1 FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE PHAX, ALKBH1, JMJD6 FTO 770/4885HPGD 4470/4885MEN1 2992/4885
US-11021504-B2 Functionalization and purification of molecules by reversible group exchange PHAX, ALKBH1, JMJD6 FTO 770/4885HPGD 4470/4885MEN1 2992/4885
US-20210277043-A1 FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE PHAX, ALKBH1, JMJD6 FTO 770/4885HPGD 4470/4885MEN1 2992/4885
US-11760772-B2 Functionalization and purification of molecules by reversible group exchange PHAX, ALKBH1, JMJD6 FTO 770/4885HPGD 4470/4885MEN1 2992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.